Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


All in favor say ‘eye’

Executive Summary

Bausch & Lomb's Optura (besifloxacin ophthalmic suspension) receives unanimous support Dec. 5 for treatment of bacterial conjunctivitis. Members of FDA's Dermatologic and Ophthalmic Drugs Advisory Committee added no hesitations or qualifications to their 9-0 vote that besifloxacin's benefits outweigh its risks, agreeing with FDA's conclusions that the sponsor conducted three adequate and well-controlled trials supporting the drug's efficacy

You may also be interested in...

Pfizer, Bausch & Lomb Team Up On Ophthalmology

U.S. co-promotion will combine sales forces to promote Pfizer’s Xalatan and Bausch & Lomb’s Alrex, Lotemex, Zylet and besifloxacin.

Teva Calls In Sanofi To Turbocharge Its Place In Blockbuster TL1A Inflammation Race

Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.

Novo Mulls What To Do With Wegovy Windfall

The fortunes of the foundation that controls Novo Nordisk and backs a wide range of scientific, humanitarian and social causes are set to be transformed by the spectacular commercial success of the weight loss blockbuster Wegovy.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts